Pretreatment of donor islets with papain improves allograft survival without systemic immunosuppression in mice

Kenjiro Kumano, Hitomi Nishinakamura, Toshiyuki Mera, Takeshi Itoh, Hiroyuki Takahashi, Toshiyoshi Fujiwara, Shohta Kodama

Research output: Contribution to journalArticle

Abstract

Although current immunosuppression protocols improve the efficacy of clinical allogenic islet transplantation, T cell-mediated allorejection remains unresolved, and major histocompatibility complexes (MHCs) play a crucial role in this process. Papain, a cysteine protease, has the unique ability to cleave the extracellular domain of the MHC class I structure. We hypothesized that pretreatment of donor islets with papain would diminish the expression of MHC class I on islets, reducing allograft immunogenicity and contributing to prolongation of islet allograft survival. BALB/c islets pretreated with papain were transplanted into C57BL/6J mice as an acute allorejection model. Treatment with 1 mg/mL papain significantly prolonged islet allograft survival. In vitro, to determine the inhibitory effect on T cell-mediated alloreactions, we performed lymphocyte proliferation assays and mixed lymphocyte reactions. Host T cell activation against allogenic islet cells was remarkably suppressed by pretreatment of donor islet cells with 10 mg/mL papain. Flow cytometric analysis was also performed to investigate the effect of papain treatment on the expression of MHC class I on islets. One or 10 mg/mL papain treatment reduced MHC class I expression on the islet cell surface. Pretreatment of donor islets with papain suppresses MHC class I-mediated allograft rejection in mice and contributes to prolongation of islet allograft survival without administration of systemic immunosuppressants. These results suggest that pretreatment of human donor islets with papain may reduce the immunogenicity of the donor islets and minimize the dosage of systemic immunosuppressants required in a clinical setting.

Original languageEnglish
Pages (from-to)145-155
Number of pages11
JournalIslets
Volume8
Issue number5
DOIs
Publication statusPublished - Sep 2 2016

Fingerprint

Papain
Immunosuppression
Allografts
Major Histocompatibility Complex
Islets of Langerhans
Immunosuppressive Agents
T-Lymphocytes
Islets of Langerhans Transplantation
Mixed Lymphocyte Culture Test
Cysteine Proteases
Homologous Transplantation
Inbred C57BL Mouse
Therapeutics
Lymphocytes

Keywords

  • allorejection
  • islet transplantation
  • MHC class I
  • papain
  • T cell

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Pretreatment of donor islets with papain improves allograft survival without systemic immunosuppression in mice. / Kumano, Kenjiro; Nishinakamura, Hitomi; Mera, Toshiyuki; Itoh, Takeshi; Takahashi, Hiroyuki; Fujiwara, Toshiyoshi; Kodama, Shohta.

In: Islets, Vol. 8, No. 5, 02.09.2016, p. 145-155.

Research output: Contribution to journalArticle

Kumano, Kenjiro ; Nishinakamura, Hitomi ; Mera, Toshiyuki ; Itoh, Takeshi ; Takahashi, Hiroyuki ; Fujiwara, Toshiyoshi ; Kodama, Shohta. / Pretreatment of donor islets with papain improves allograft survival without systemic immunosuppression in mice. In: Islets. 2016 ; Vol. 8, No. 5. pp. 145-155.
@article{e0396e5e28424c12953f038ffc76fd5c,
title = "Pretreatment of donor islets with papain improves allograft survival without systemic immunosuppression in mice",
abstract = "Although current immunosuppression protocols improve the efficacy of clinical allogenic islet transplantation, T cell-mediated allorejection remains unresolved, and major histocompatibility complexes (MHCs) play a crucial role in this process. Papain, a cysteine protease, has the unique ability to cleave the extracellular domain of the MHC class I structure. We hypothesized that pretreatment of donor islets with papain would diminish the expression of MHC class I on islets, reducing allograft immunogenicity and contributing to prolongation of islet allograft survival. BALB/c islets pretreated with papain were transplanted into C57BL/6J mice as an acute allorejection model. Treatment with 1 mg/mL papain significantly prolonged islet allograft survival. In vitro, to determine the inhibitory effect on T cell-mediated alloreactions, we performed lymphocyte proliferation assays and mixed lymphocyte reactions. Host T cell activation against allogenic islet cells was remarkably suppressed by pretreatment of donor islet cells with 10 mg/mL papain. Flow cytometric analysis was also performed to investigate the effect of papain treatment on the expression of MHC class I on islets. One or 10 mg/mL papain treatment reduced MHC class I expression on the islet cell surface. Pretreatment of donor islets with papain suppresses MHC class I-mediated allograft rejection in mice and contributes to prolongation of islet allograft survival without administration of systemic immunosuppressants. These results suggest that pretreatment of human donor islets with papain may reduce the immunogenicity of the donor islets and minimize the dosage of systemic immunosuppressants required in a clinical setting.",
keywords = "allorejection, islet transplantation, MHC class I, papain, T cell",
author = "Kenjiro Kumano and Hitomi Nishinakamura and Toshiyuki Mera and Takeshi Itoh and Hiroyuki Takahashi and Toshiyoshi Fujiwara and Shohta Kodama",
year = "2016",
month = "9",
day = "2",
doi = "10.1080/19382014.2016.1223579",
language = "English",
volume = "8",
pages = "145--155",
journal = "Islets",
issn = "1938-2014",
publisher = "Landes Bioscience",
number = "5",

}

TY - JOUR

T1 - Pretreatment of donor islets with papain improves allograft survival without systemic immunosuppression in mice

AU - Kumano, Kenjiro

AU - Nishinakamura, Hitomi

AU - Mera, Toshiyuki

AU - Itoh, Takeshi

AU - Takahashi, Hiroyuki

AU - Fujiwara, Toshiyoshi

AU - Kodama, Shohta

PY - 2016/9/2

Y1 - 2016/9/2

N2 - Although current immunosuppression protocols improve the efficacy of clinical allogenic islet transplantation, T cell-mediated allorejection remains unresolved, and major histocompatibility complexes (MHCs) play a crucial role in this process. Papain, a cysteine protease, has the unique ability to cleave the extracellular domain of the MHC class I structure. We hypothesized that pretreatment of donor islets with papain would diminish the expression of MHC class I on islets, reducing allograft immunogenicity and contributing to prolongation of islet allograft survival. BALB/c islets pretreated with papain were transplanted into C57BL/6J mice as an acute allorejection model. Treatment with 1 mg/mL papain significantly prolonged islet allograft survival. In vitro, to determine the inhibitory effect on T cell-mediated alloreactions, we performed lymphocyte proliferation assays and mixed lymphocyte reactions. Host T cell activation against allogenic islet cells was remarkably suppressed by pretreatment of donor islet cells with 10 mg/mL papain. Flow cytometric analysis was also performed to investigate the effect of papain treatment on the expression of MHC class I on islets. One or 10 mg/mL papain treatment reduced MHC class I expression on the islet cell surface. Pretreatment of donor islets with papain suppresses MHC class I-mediated allograft rejection in mice and contributes to prolongation of islet allograft survival without administration of systemic immunosuppressants. These results suggest that pretreatment of human donor islets with papain may reduce the immunogenicity of the donor islets and minimize the dosage of systemic immunosuppressants required in a clinical setting.

AB - Although current immunosuppression protocols improve the efficacy of clinical allogenic islet transplantation, T cell-mediated allorejection remains unresolved, and major histocompatibility complexes (MHCs) play a crucial role in this process. Papain, a cysteine protease, has the unique ability to cleave the extracellular domain of the MHC class I structure. We hypothesized that pretreatment of donor islets with papain would diminish the expression of MHC class I on islets, reducing allograft immunogenicity and contributing to prolongation of islet allograft survival. BALB/c islets pretreated with papain were transplanted into C57BL/6J mice as an acute allorejection model. Treatment with 1 mg/mL papain significantly prolonged islet allograft survival. In vitro, to determine the inhibitory effect on T cell-mediated alloreactions, we performed lymphocyte proliferation assays and mixed lymphocyte reactions. Host T cell activation against allogenic islet cells was remarkably suppressed by pretreatment of donor islet cells with 10 mg/mL papain. Flow cytometric analysis was also performed to investigate the effect of papain treatment on the expression of MHC class I on islets. One or 10 mg/mL papain treatment reduced MHC class I expression on the islet cell surface. Pretreatment of donor islets with papain suppresses MHC class I-mediated allograft rejection in mice and contributes to prolongation of islet allograft survival without administration of systemic immunosuppressants. These results suggest that pretreatment of human donor islets with papain may reduce the immunogenicity of the donor islets and minimize the dosage of systemic immunosuppressants required in a clinical setting.

KW - allorejection

KW - islet transplantation

KW - MHC class I

KW - papain

KW - T cell

UR - http://www.scopus.com/inward/record.url?scp=84987748066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987748066&partnerID=8YFLogxK

U2 - 10.1080/19382014.2016.1223579

DO - 10.1080/19382014.2016.1223579

M3 - Article

VL - 8

SP - 145

EP - 155

JO - Islets

JF - Islets

SN - 1938-2014

IS - 5

ER -